Co., Ltd. ("LongBio"), a clinical-stage biotech company focused on discovery and development of biologics targeting allergic and autoimmune diseases, proudly announced positive topline results from a ...

Final stage of the OUtMATCH trial tracks outcomes for oral immunotherapy versus omalizumab ...

Dupilumab did significantly reduce the gastrointestinal (GI) symptoms, like vomiting, diarrhea, and abdominal pain within 2 ...

Patients with chronic spontaneous urticaria and positive CU Index results or a combination of low IgE and low blood histamine content were more likely to have a poor response to omalizumab, according ...

Omalizumab shows superior efficacy to dupilumab in reducing symptoms in patients with chronic spontaneous urticaria.

Omalizumab, both as a monotherapy and for oral immunotherapy (OIT), modulates specific T cell and dendritic cell (DC) subsets, increasing patient's reaction thresholds to common food allergens, ...

Please provide your email address to receive an email when new articles are posted on . 87.3% of white patients and 92.8% of Black patients had no severe exacerbations with omalizumab. 4% of white ...

This is a case study of a male patient with Fabry disease who presented with severe anaphylaxis following re-initiation of full-strength treatment with intravenous agalsidase beta (Fabrazyme). A ...

Among those who received omalizumab, a 1044 mg dose of 1, 2, and 3 allergenic foods had no adverse effect in 80%, 69%, and 47% of participants, respectively. Omalizumab for 16 weeks increased the ...

Findings showed equivalent efficacy in change from baseline in weekly itch severity score between omalizumab-igec 300mg and Xolair 300mg. The Food and Drug Administration (FDA) has approved Omlyclo ® ...

More than 60% of participant dietary consumption plans showed no significant difference between omalizumab and multi-food oral immunotherapy success rates after 12 months MILWAUKEE , Feb.

The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of omalizumab, having considered evidence on the nature of chronic spontaneous urticaria and the value placed ...